middle.news
Argent BioPharma opens new antiviral lane with NLC portfolio licence
8:40am on Tuesday 29th of September, 2026 AEST
•
Biopharmaceuticals
Read Story
Argent BioPharma opens new antiviral lane with NLC portfolio licence
8:40am on Tuesday 29th of September, 2026 AEST
Key Points
Exclusive antiviral commercialisation rights across most markets
US$15,000 monthly fee for 20 months
Tiered royalties of 6% to 12% on product sales
Potential issue of 2 million performance rights
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE